BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/16/2021 8:48:21 AM | Browse: 646 | Download: 1602
 |
Received |
|
2021-05-08 03:08 |
|
Peer-Review Started |
|
2021-05-08 03:10 |
|
First Decision by Editorial Office Director |
|
2021-06-05 14:38 |
|
Return for Revision |
|
2021-06-05 14:38 |
|
Revised |
|
2021-06-17 06:46 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-07-05 05:50 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-07-05 06:59 |
|
Articles in Press |
|
2021-07-05 06:59 |
|
Edit the Manuscript by Language Editor |
|
2021-07-13 23:34 |
|
Typeset the Manuscript |
|
2021-09-13 01:38 |
|
Publish the Manuscript Online |
|
2021-09-16 08:48 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F benefits from both afatinib and osimertinib: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yao Zhang, Ji-Qiao Shen, Lin Shao, Yan Chen, Lei Lei and Jia-Lei Wang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jia-Lei Wang, MD, Chief Physician, Department of Medical Oncology, Fudan University Shanghai Cancer Center, No. 270 Dongan Road, Shanghai 200032, China. m18017312369@163.com |
| Key Words |
Afatinib; Osimertinib; Epidermal growth factor receptor; L861Q-L833F; Non-small cell lung cancer; Case report |
| Core Tip |
Our case revealed that both afatinib and the osimertinib + bevacizumab combination demonstrated clinical efficacy in a non-small cell lung cancer patient harboring rare epidermal growth factor receptor (EGFR) L833F-L861Q. The results provide more options for the clinical management of patients with rare EGFR compound mutations. |
| Publish Date |
2021-09-16 08:48 |
| Citation |
Zhang Y, Shen JQ, Shao L, Chen Y, Lei L, Wang JL. Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F benefits from both afatinib and osimertinib: A case report. World J Clin Cases 2021; 9(27): 8220-8225 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i27/8220.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i27.8220 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
